New Study Reveals Promising Results for Belantamab Mafodotin Combination Therapy
Authored by Mike Bassett, a Staff Writer at MedPage Today, on June 2, 2024.
An innovative phase III trial presented at the American Society of Clinical Oncology (ASCO) conference highlighted the impressive effectiveness of combining belantamab mafodotin (belamaf; Blenrep) with pomalidomide (Pomalyst) and dexamethasone (BPd) in improving progression-free survival (PFS) rates for patients dealing with relapsed/refractory multiple myeloma, surpassing traditional treatment methods.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
